The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Written informed consent and HIPAA authorization for release of personal health information.
Age ≥ 18 years of age at the time of enrollment
Confirmed diagnosis of AML
Planned initial treatment with azacitidine and venetoclax
None
Wake Forest University Health Sciences
Lead sponsor
Atrium Health Levine Cancer Institute
Collaborator
Swim Across America
Collaborator